Regorafenib showed promise compared to standard of care in the randomised multi-institutional investigator-sponsored Phase 2 trial REGOMA, published in The Lancet Oncology in December, 2018.
Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback